Persistent activation of nuclear factor kappa-B signaling pathway in patients with unstable angina and elevated levels of C-reactive protein evidence for a direct proinflammatory effect of azide and lipopolysaccharide-free C-reactive protein on human monocytes via nuclear factor kappa-B activation.

[1]  Y. Kureishi,et al.  Rho/Rho-Kinase Pathway Contributes to C-Reactive Protein–Induced Plasminogen Activator Inhibitor-1 Expression in Endothelial Cells , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[2]  T. Sawamura,et al.  Enhanced plasma levels of oxidized low-density lipoprotein increase circulating nuclear factor-kappa B activation in patients with unstable angina. , 2005, Journal of the American College of Cardiology.

[3]  Paul Schoenhagen,et al.  Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. , 2005, The New England journal of medicine.

[4]  M. Pfeffer,et al.  C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.

[5]  M. Kutryk,et al.  C-Reactive Protein Attenuates Endothelial Progenitor Cell Survival, Differentiation, and Function: Further Evidence of a Mechanistic Link Between C-Reactive Protein and Cardiovascular Disease , 2004, Circulation.

[6]  N. Cheshire,et al.  Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[7]  C. Monaco,et al.  Nuclear factor kappaB: a potential therapeutic target in atherosclerosis and thrombosis. , 2004, Cardiovascular research.

[8]  S. Devaraj,et al.  Effect of C-reactive protein on chemokine expression in human aortic endothelial cells. , 2004, Journal of molecular and cellular cardiology.

[9]  S. Verma,et al.  C-reactive protein activates the nuclear factor-kappaB signal transduction pathway in saphenous vein endothelial cells: implications for atherosclerosis and restenosis. , 2003, The Journal of thoracic and cardiovascular surgery.

[10]  E. Yeh,et al.  Inflammatory Cytokines Stimulated C-Reactive Protein Production by Human Coronary Artery Smooth Muscle Cells , 2003, Circulation.

[11]  S. Devaraj,et al.  C-Reactive Protein Decreases Prostacyclin Release From Human Aortic Endothelial Cells , 2003, Circulation.

[12]  Mark B Pepys,et al.  C-reactive protein: a critical update. , 2003, The Journal of clinical investigation.

[13]  S. Verma,et al.  C-Reactive Protein Upregulates Angiotensin Type 1 Receptors in Vascular Smooth Muscle , 2003, Circulation.

[14]  Y. Hattori,et al.  Vascular smooth muscle cell activation by C-reactive protein. , 2003, Cardiovascular research.

[15]  A. Hoffmann,et al.  The I (cid:1) B –NF-(cid:1) B Signaling Module: Temporal Control and Selective Gene Activation , 2022 .

[16]  Ren-Ke Li,et al.  A Self-Fulfilling Prophecy: C-Reactive Protein Attenuates Nitric Oxide Production and Inhibits Angiogenesis , 2002, Circulation.

[17]  S. Verma,et al.  Endothelin Antagonism and Interleukin-6 Inhibition Attenuate the Proatherogenic Effects of C-Reactive Protein , 2002, Circulation.

[18]  Nader Rifai,et al.  Multimarker Approach to Risk Stratification in Non-ST Elevation Acute Coronary Syndromes: Simultaneous Assessment of Troponin I, C-Reactive Protein, and B-Type Natriuretic Peptide , 2002, Circulation.

[19]  S. Marsch,et al.  Inflammation and Long-Term Mortality After Non-ST Elevation Acute Coronary Syndrome Treated With a Very Early Invasive Strategy in 1042 Consecutive Patients , 2002, Circulation.

[20]  W. Edwards,et al.  Nuclear factor-κB immunoreactivity is present in human coronary plaque and enhanced in patients with unstable angina pectoris , 2002 .

[21]  W. Edwards,et al.  Nuclear factor-kappaB immunoreactivity is present in human coronary plaque and enhanced in patients with unstable angina pectoris. , 2002, Atherosclerosis.

[22]  V. Pasceri,et al.  C-reactive protein: linking inflammation to cardiovascular complications. , 2001, Circulation.

[23]  G. Hansson,et al.  Nuclear factor kappa-B and the heart. , 2001, Journal of the American College of Cardiology.

[24]  James T. Willerson,et al.  Modulation of C-Reactive Protein–Mediated Monocyte Chemoattractant Protein-1 Induction in Human Endothelial Cells by Anti-Atherosclerosis Drugs , 2001 .

[25]  A. Maseri,et al.  Enhanced Response of Blood Monocytes to In Vitro Lipopolysaccharide-Challenge in Patients With Recurrent Unstable Angina , 2001, Circulation.

[26]  R. Frye,et al.  Molecular Fingerprint of Interferon-&ggr; Signaling in Unstable Angina , 2001, Circulation.

[27]  A. Aljada,et al.  Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. , 2001, The Journal of clinical endocrinology and metabolism.

[28]  M. Cybulsky,et al.  NF-κB: pivotal mediator or innocent bystander in atherogenesis? , 2001 .

[29]  M. Cybulsky,et al.  NF-kappaB: pivotal mediator or innocent bystander in atherogenesis? , 2001, The Journal of clinical investigation.

[30]  James T. Willerson,et al.  Direct Proinflammatory Effect of C-Reactive Protein on Human Endothelial Cells , 2000, Circulation.

[31]  A. Siegbahn,et al.  Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. , 2000, The New England journal of medicine.

[32]  W. Koenig,et al.  C-Reactive Protein in the Arterial Intima: Role of C-Reactive Protein Receptor–Dependent Monocyte Recruitment in Atherogenesis , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[33]  C. Geczy,et al.  C-reactive Protein : Relationship with Age, Sex, and Hormone Replacement Treatment and Lipopolysaccharide Potentiate Monocyte Tissue Factor Induction by Γ Interferon- Interferon-␥ and Lipopolysaccharide Potentiate Monocyte Tissue Factor Induction by C-reactive Protein Relationship with Age, Sex, and , 2022 .

[34]  中込 明裕.  Interferon-γ and Lipopolysaccharide Potentiate Monocyte Tissue Factor Induction by C-Reactive Protein Relationship With Age, Sex, and Hormone Replacement treatment , 2000 .

[35]  A. Rebuzzi,et al.  Enhanced inflammatory response in patients with preinfarction unstable angina. , 1999, Journal of the American College of Cardiology.

[36]  T. Böhm,et al.  Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. , 1999, Circulation.

[37]  S. Bhakdi,et al.  Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[38]  W. Cliff,et al.  Coronary C-reactive protein distribution: its relation to development of atherosclerosis. , 1999, Atherosclerosis.

[39]  C. Visser,et al.  C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? , 1999, Circulation.

[40]  A. Rebuzzi,et al.  Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. , 1999, Circulation.

[41]  M. E. Ritchie.  Nuclear Factor-κB Is Selectively and Markedly Activated in Humans With Unstable Angina Pectoris , 1998 .

[42]  E. Antman,et al.  C-Reactive Protein Is a Potent Predictor of Mortality Independently of and in Combination With Troponin T in Acute Coronary Syndromes: A TIMI 11A Substudy , 1998 .

[43]  E. Antman,et al.  C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. , 1998, Journal of the American College of Cardiology.

[44]  M. Karin,et al.  Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. , 1997, The New England journal of medicine.

[45]  G. Ciliberto,et al.  Elevated levels of interleukin-6 in unstable angina. , 1996, Circulation.

[46]  C. Marsh,et al.  Acute phase levels of C-reactive protein enhance IL-1 beta and IL-1ra production by human blood monocytes but inhibit IL-1 beta and IL-1ra production by alveolar macrophages. , 1996, Journal of immunology.

[47]  A. Rebuzzi,et al.  The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. , 1994, The New England journal of medicine.

[48]  Harry,et al.  C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. , 1993, Blood.

[49]  G. Lozanski,et al.  Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. , 1992, Cytokine.

[50]  H. Buller,et al.  ENDOTOXAEMIA: AN EARLY PREDICTOR OF SEPTICAEMIA IN FEBRILE PATIENTS , 1988, The Lancet.

[51]  Germaine Greer,et al.  van Deventer H , 1968 .